Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.14670/HH-18-657
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Wang, Min | - |
dc.contributor.author | Liu, Kai | - |
dc.contributor.author | Zhou, Zhongming | - |
dc.contributor.author | Geng, Huizhuan | - |
dc.date.accessioned | 2024-04-10T08:28:05Z | - |
dc.date.available | 2024-04-10T08:28:05Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Histology and Histopathology Vol. 39, nº4 (2024) | es |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.uri | http://hdl.handle.net/10201/140670 | - |
dc.description.abstract | Background. The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer. Methods. Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638. Results. Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638. Conclusion. We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatment | es |
dc.format | application/pdf | es |
dc.format.extent | 13 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia, Departamento de Biologia Celular e Histiologia | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | miR-638 | es |
dc.subject | NCAPG2 | es |
dc.subject | Tetrandrine | es |
dc.subject | Cervical cancer | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es |
dc.title | miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrine | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | https://doi.org/10.14670/HH-18-657 | - |
Aparece en las colecciones: | Vol.39, nº4 (2024) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Wang-39-497-509-2024 (1).pdf | 8,78 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons